You are here: Industry Insights > gilead

News List

India to import 4.5 lakh vials of Remdesivir expresspharma
May 06, 2021
The government has started importing the vital drug Remdesivir from other countries to ease its shortage in the country.
Gilead Revenues up 16% in the Quarter contractpharma
May 06, 2021
Veklury drives growth in the quarter, offsetting significant declines in HIV, HCV franchises.
Gilead Sciences to support expansion of local production capacity of Remdesivir in India expresspharma
April 28, 2021
Gilead will donate a minimum of 450,000 vials of Veklury to the Government of India.
Gilead’s Trodelvy scores accelerated approval in advanced bladder cancer pharmatimes
April 15, 2021
Gilead’s antibody drug conjugate (ADC) Trodelvy has received an accelerated approval from the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic urothelial cancer (UC), the most common form of bladder cancer.
Gilead gets US FDA Accelerated Approval for Trodelvy to treat metastatic urothelial cancer expresspharma
April 15, 2021
Gilead Sciences announced that the US Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously ...
Gilead gets US FDA nod for Trodelvy to treat metastatic triple-negative breast cancer expresspharma
April 09, 2021
Trodelvy significantly reduced the risk of death by 49 per cent compared with single-agent chemotherapy in the Phase 3 ASCENT Study.
AbCellera, Gilead collaborate for new multi-year, multi-target antibody discovery expresspharma
April 02, 2021
AbCellera announced agreements to expand its collaboration with Gilead Sciences including a multi-year, multi-target antibody discovery collaboration and access to AbCellera’s humanised mouse technology, the Trianni Mouse.
EMA validates Gilead Sciences’ application for breast cancer therapy pharmaceutical-business-review
March 31, 2021
The European Medicines Agency (EMA) has validated Gilead Sciences’ marketing authorization application (MAA) for sacituzumab govitecan-hziy (SG) to treat advanced breast cancer.
Gilead, Novo Nordisk expand NASH clinical collaboration expresspharma
March 19, 2021
Gilead Sciences and Novo Nordisk announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).
Gilead, Merck sign pact to develop, commercialise long-acting HIV treatment combinations expresspharma
March 16, 2021
Gilead Sciences and Merck, known as MSD outside the US and Canada, announced that they have entered into an agreement to co-develop and co-commercialise long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page